Document is current
Any future updates will be listed below
-
Authors
Llovet, Josep M. https://orcid.org/0000-0003-0547-2667
De Baere, Thierry
Kulik, Laura
Haber, Philipp K.
Greten, Tim F. https://orcid.org/0000-0002-0806-2535
Meyer, Tim
Lencioni, Riccardo
- License Information
-
More Information
Article History
Accepted: 25 November 2020
First Online: 28 January 2021
Competing interests
: J.M.L. receives research support from Bayer HealthCare Pharmaceuticals, Boehringer-Ingelheim, Bristol-Myers Squibb, Eisai Inc. and Ipsen. He has also received consulting fees from AstraZeneca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Can-Fite, Celsion Corporation, Eisai Inc., Eli Lilly, Glycotest, Ipsen, Merck, Nucleix, Roche and Sirtex. T.D.B. has received research support from Boston-Scientific Galil, and Terumo, and advisory board fees from AstraZeneca, Boston-Scientific, Esai, Guerbet and Terumo. L.K. receives consulting fees from Bayer, Eisai, Exelixis, Gilead and Merck, and research funding from Glycotest and TARGET-HCC. T.M. has received advisory board fees from AstraZeneca, BTG, Eisai, Ipsen, Roche and Tarveda. The remaining co-authors declare no competing interests.
